|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,458.40 INR | +1.42% |
|
+3.01% | +6.88% |
Business description: Emcure Pharmaceuticals Limited
Number of employees: 6,731
Sales by Activity: Emcure Pharmaceuticals Limited
| Fiscal Period: March | 2021 (INR) | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) |
|---|---|---|---|---|---|
Pharmaceuticals | 6.06TCr | 5.86TCr | 5.99TCr | 6.66TCr | 7.9TCr |
Geographical breakdown of sales: Emcure Pharmaceuticals Limited
| Fiscal Period: March | 2021 (INR) | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) |
|---|---|---|---|---|---|
India | 2.48TCr | 3.2TCr | 3.18TCr | 3.21TCr | 3.66TCr |
Europe | 738.31Cr | 896.82Cr | 1.19TCr | 1.42TCr | 1.53TCr |
ROW | 1.13TCr | 1.07TCr | 887.25Cr | 1.09TCr | 1.41TCr |
North America | 1.71TCr | 679.45Cr | 729.42Cr | 927.91Cr | 1.3TCr |
Executive Committee: Emcure Pharmaceuticals Limited
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 75 | 16/04/1981 | |
| Director of Finance/CFO | - | 01/10/2003 | |
Deepak Gondaliya
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Chief Operating Officer | 45 | 28/07/2022 | |
| Chief Tech/Sci/R&D Officer | 72 | 23/07/2001 |
Composition of the Board of Directors: Emcure Pharmaceuticals Limited
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 69 | - | |
| Director/Board Member | 72 | 23/07/2001 | |
| Director/Board Member | 75 | 16/04/1981 | |
| Director/Board Member | 49 | 28/07/2019 | |
| Director/Board Member | 45 | 28/07/2022 | |
| Director/Board Member | 63 | 05/06/2013 | |
| Director/Board Member | 63 | 22/07/2020 | |
| Director/Board Member | 71 | 16/04/2021 | |
Vijay Gokhale
BRD | Director/Board Member | 67 | 16/04/2021 |
| Director/Board Member | 61 | 16/04/2021 |
Company details: Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Ltd.
Plot No. P-1 & P-2, IT-BT Park
411057, Pune
+91 20 3507 0033
http://www.emcure.com
Group companies: Emcure Pharmaceuticals Limited
| Name | Category and Sector |
|---|---|
Heritage Pharma Holdings, Inc.
 Heritage Pharma Holdings, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceutical products |
Pharmaceuticals: Major
|
Heritage Pharma Holdings, Inc.
Heritage Pharma Holdings, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceutical products |
Pharmaceuticals: Major
|
Zuventus Healthcare Ltd.
 Zuventus Healthcare Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company |
Pharmaceuticals: Major
|
Zuventus Healthcare Ltd.
Zuventus Healthcare Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company |
Pharmaceuticals: Major
|
Gennova Biopharmaceuticals Ltd.
 Gennova Biopharmaceuticals Ltd. Miscellaneous Commercial ServicesCommercial Services Focuses on biotechnology research for biosimilars, vaccines and monoclonal antibodies using recombinant DNA technology |
Miscellaneous Commercial Services
|
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.42% | +3.01% | +57.21% | - | 294.76Cr | |
| +0.41% | -1.91% | +19.93% | +200.16% | 88TCr | |
| +0.69% | +0.25% | +49.34% | +57.88% | 58TCr | |
| +0.81% | -2.64% | +3.25% | +42.59% | 39TCr | |
| +0.50% | -5.54% | +5.40% | +21.46% | 32TCr | |
| -0.11% | -0.94% | +19.76% | +34.95% | 30TCr | |
| +0.07% | -1.48% | +26.04% | +60.91% | 29TCr | |
| +0.58% | -1.43% | +21.77% | +7.54% | 29TCr | |
| +0.01% | -2.84% | +15.47% | +56.14% | 20TCr | |
| +0.15% | -0.97% | +29.35% | +81.85% | 18TCr | |
| Average | +0.54% | -2.03% | +24.75% | +62.61% | 34.29TCr | |
| Weighted average by Cap. | +0.46% | -1.37% | +22.59% | +84.49% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- EMCURE Stock
- Company Emcure Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition